This website is for UK healthcare professionals and UK healthcare decision makers only

Reporting adverse events
A
A
Prescribing information for:

Ferinject 
(ferric carboxymaltose)

Kapruvia ▼
(difelikefalin)

Tavneos ▼
(avacopan)

Veltassa 
(patiromer)

Venofer 
(iron sucrose)

Find out more about how treatment with
TAVNEOS® (avacopan) could support your
treatment goals for patients with AAV (GPA/MPA)

FERINJECT®
(ferric carboxymaltose)

KAPRUVIA®(difelikefalin)

TAVNEOS®(avacopan)

VELTASSA®
(patiromer)

WEBINARS
AND EVENTS

TARGETING IMPROVED
CONTROL IN AAV (GPA/MPA)

INTRODUCING TAVNEOS®
TAVNEOS, with a cyclophosphamide or rituximab regimen, is recommended by NICE, within its marketing authorisation, as an option for treating severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in adults1,2

TARGETING IMPROVED
CONTROL IN AAV (GPA/MPA)

INTRODUCING TAVNEOS®
TAVNEOS, with a cyclophosphamide or rituximab regimen, is recommended by NICE, within its marketing authorisation, as an option for treating severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in adults1,2

AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic antibody; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis;

NICE, National Institute for Health and Care Excellence.

 

AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic antibody; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; NICE, National Institute for Health and Care Excellence.

 
Adverse events should be reported. Reporting forms and information for United Kingdom can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Pharma Ltd. Tel: +44 1276 853633. E-mail: medicalInfo_UK@viforpharma.com
References

1. TAVNEOS GB SmPC. 2. NICE (2022). Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis. Available at:https://www.nice.org.uk/guidance/TA825. Last accessed: December 2023.

More Resources

Ferinject

Resources

Veltassa

Resources

You are now heading to a third-party website that we do
not operate. We are not responsible for the content of the
third-party website. You are advised to review its privacy policy
as it may differ from ours.

 

Are you sure you want to leave?

Confirm

Cancel

Report adverse events in the UK:

Adverse events should be reported. Reporting forms and information for United Kingdom can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Pharma Ltd. Tel: +44 1276 853633. E-mail: medicalInfo_UK@viforpharma.com